This R21 grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $219,491 to Mayo Clinic Jacksonville to investigate the role of the protein SIRT6 in regulating T cell metabolism and immune function in the tumor microenvironment. The overall goal is to understand how SIRT6 impairs the ability of tumor-infiltrating T cells to mount an effective anti-tumor immune response, and to determine whether inhibiting SIRT6 can enhance T cell metabolism and function to improve cancer immunotherapy. The research will utilize in vitro studies with primary mouse and human T cells as well as in vivo patient-derived xenograft tumor models. The findings are expected to validate SIRT6 as a novel metabolic and immunologic target for enhancing cancer immunotherapies.
Generated 1/28/25, 9:59 AM